Ondine Biomedical Inc. Annual Report for the Year Ended 31 December 2022 (2523A)
23 May 2023 - 4:00PM
UK Regulatory
TIDMOBI
RNS Number : 2523A
Ondine Biomedical Inc.
23 May 2023
23 May 2023
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Annual Report for the Year Ended 31 December 2022
Ondine Biomedical (AIM: OBI) announces that its Annual Report
for the year ended 31 December 2022 was posted on 23 May 2022 and
is available on the Ondine website at:
https://ondinebio.com/investors/reports-documentation/
Ondine Biomedical Inc.
+001 (1) 604 838
Angelika Vance, Corporate Communications 2702
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0) 20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0) 77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Ondine's nasal photodisinfection technology is approved in several
jurisdictions under the brand name Steriwave(TM). It has been
awarded the CE mark and, in the US, has been granted Qualified
Infectious Disease Product designation and Fast Track status by the
FDA. Products beyond nasal photodisinfection include therapies for
a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSBLGDURDDDGXD
(END) Dow Jones Newswires
May 23, 2023 02:00 ET (06:00 GMT)
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From Mar 2024 to May 2024
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From May 2023 to May 2024